Alpha-synuclein induced synucleinopathies and NBIA's

I thought of writing this to perhaps discuss the elephant in the room....

I know of the discussions of ATH 434 are around MSA/ PD and now freidrech's ataxia.

Just taking a step back and looking at the chart on Alterity's website-

https://alteritytherapeutics.com/wp-content/uploads/-84



They do mention Neurodegenerative diseases in discovery.

Broadly if we were to break this up into 2 categories:
1) Alpha-synuclein synucleinopathies would include but not limited to :
a) PD
b) MSA
c) Dementia with Lewy bodies
d) REM sleep behaviour disorder
e) Pure autonomic failure

2) Neurodegeneration with Brain Iron Accumulation (NBIA)

a) PKAN, or Pantothenic Kinase-Associated Neurodegeneration
b) PLAN, or PLA2G6-Associated Neurodegeneration
c) MPAN, or Mitochondrial-membrane Protein-Associated Neurodegeneration
d) BPAN, or Beta-propeller Protein-Associated Neurodegeneration
e) FAHN, or Fatty Acid Hydroxylase-associated Neurodegeneration
f) Kufor-Rakeb disease
g) Neuroferritinopathy
h) Woodhouse-Sakati Syndrome
i) CoPan
j) Idiopathic NBIA


I know the NBIa's are genetically medicated and there might be someone researching a drug for these conditions and they are very rare (small market). But my point here is that if these conditions are exacerbated by iron accumulation then perhaps ATH 434 has a role to play in disease modification/regression ? I understand undertaking studies is expensive but if it did show success then imagine the immense help to these patients as well as the company!

Coming back to the alpha synuclien , dementia with Lewy bodies affects unto 1.4 million people in the US alone which is 5% of the dementia's diagnosed. I am not sure if anyone has even addressed the application of the drug in this condition.

Apart from this what I could find was:

1) Poststroke Induction of α-Synuclein Mediates Ischemic Brain Damage

2) Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics? Published for Percheron's drug

3) Alzheimers


I am sure I have missed some other potential diseases/disorders where ATH 434 could be used, so feel free to add to this.

I guess if this were to be taken up by BP, then they would be looking at the above conditions and market size etc licking their lips...

DYOR, this is not financial advice